Corporate Responsibility Report 2024

Alnylam was named to Newsweek's responsible companies list for the third consecutive year.

The company moved from #422 in 2023 to #153 in 2025.

Alnylam revisited its Patient Access Philosophy in 2024 to expand its reach.

The philosophy was established in 2017.

Alnylam launched a Patient Perspectives series in 2024 to help employees understand patient experiences.

The series helps employees understand the experiences of patients, caregivers, and advocates.

Alnylam focused on cardiovascular provider collaboration in 2024 to engage global specialists.

The company engaged global cardiologists and other specialists to understand their needs. This focus is due to two approved medicines and a robust pipeline.

Alnylam's modular drug discovery platform utilizes a three-pronged approach to advance RNAi therapeutics.

The approach includes delivery to new tissues, enhancement of existing designs, and investment in human genetics.

1. 01
   Delivery to new tissues

   Delivery of RNAi therapeutics to new tissues
2. 02
   Enhance existing designs

   Enhancement of existing platform designs
3. 03
   Invest in genetics

   Investment in human genetics to identify drug targets

Nearly 50% of Alnylam employees participated in community impact efforts in 2024.

Participation included Community Service Week, Alnylam Challengers events, and disaster-response campaigns.

Alnylam's Kendall campus recycled, repurposed, or donated 4,484 lbs of materials in February 2024.

During Earth Day initiatives, the company recycled 688 lbs of electronic waste from its Kendall Square facility. It also recycled 330 lbs from its Norton facility.

Alnylam's 2024 corporate responsibility efforts spanned patients, science, employees, communities, and the planet.

The company revisited its patient access philosophy and launched a patient perspectives series.